Hims & Hers Health (NYSE:HIMS) Earns “Underperform” Rating from Bank of America

Hims & Hers Health (NYSE:HIMS)‘s stock had its “underperform” rating reaffirmed by research analysts at Bank of America in a research note issued on Thursday,Benzinga reports. They currently have a $21.00 price target on the stock. Bank of America‘s target price points to a potential downside of 41.69% from the stock’s current price.

Several other equities analysts also recently weighed in on the company. Citigroup reissued a “sell” rating and set a $27.00 target price on shares of Hims & Hers Health in a research report on Thursday. Truist Financial boosted their target price on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday, February 26th. Needham & Company LLC boosted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Trading Up 4.7 %

NYSE HIMS opened at $36.01 on Thursday. The stock has a market cap of $8.00 billion, a PE ratio of 81.85 and a beta of 1.37. Hims & Hers Health has a 12 month low of $11.20 and a 12 month high of $72.98. The stock’s 50 day moving average is $37.45 and its 200 day moving average is $27.31.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, analysts forecast that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares in the company, valued at $9,549,268.05. This represents a 2.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Michael Chi sold 7,259 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $32.25, for a total value of $234,102.75. Following the sale, the insider now owns 184,947 shares of the company’s stock, valued at $5,964,540.75. This trade represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,062,011 shares of company stock worth $36,892,724. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently made changes to their positions in the stock. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth $28,000. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. raised its stake in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new stake in Hims & Hers Health in the fourth quarter valued at about $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.